Drugs / RESTEN-MP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00244647 | Aug 2003 → ? | coronary restenosis | Sarepta Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00248066 | Sep 2005 → ? | coronary restenosis | Sarepta Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2007-10-25 | Sarepta Therapeutics, Inc. | Results AVI BioPharma Announces Partner Breakfast Symposium at 2007 Transcatheter Cardiovascular Therapeutics Conference sarepta.com ↗
Furthermore, the six-month IVUS showed promising results on AVI-4126 efficacy in preventing restenosis, which is comparable to DES results at our institution, |
| 2007-07-10 | Sarepta Therapeutics, Inc. | Results AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease sarepta.com ↗
AVI BioPharma, Inc. (Nasdaq:AVII) announced today that its partner Cook Medical has completed target patient enrollment and released six-month follow-up data from a Phase II clinical trial known as APPRAISAL. |
| 2006-10-31 | Sarepta Therapeutics, Inc. | Results AVI BioPharma Discusses Phase II Cardiovascular Clinical Study sarepta.com ↗
Clinicians involved in the performance of the APPRAISAL Phase II clinical study sponsored by AVI BioPharma, Inc. (Nasdaq: AVII) and AVI's partner Cook Group Inc. presented promising preliminary observations at the 18th Annual Transcatheter Cardiovascular Therapeutics conference in Washington, D.C. last week. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2007-10-25 | Sarepta Therapeutics, Inc. | AVI BioPharma Announces Partner Breakfast Symposium at 2007 Transcatheter Cardiovascular Therapeutics Conference sarepta.com ↗ |
| 2007-07-10 | Sarepta Therapeutics, Inc. | AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease sarepta.com ↗ |
| 2006-10-31 | Sarepta Therapeutics, Inc. | AVI BioPharma Discusses Phase II Cardiovascular Clinical Study sarepta.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RESTEN-MP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00248066 ↗ |
| Action | Inhibit | “stopping MYC protein production in the vessel” NCT00244647 ↗ |
| Modality | Antisense oligonucleotide | “AVI-4126, the active ingredient of RESTEN-MP, is a proprietary antisense drug designed to interfere with the ability of human <c-myc> gene to translate mRNA into MYC protein.” NCT00244647 ↗ |
| Route | Intravenous | “single intravenous slow-push dose of RESTEN-MP” NCT00244647 ↗ |
| Target | MYC | “stopping MYC protein production in the vessel” NCT00244647 ↗ |